Navigation Links
Renovis Reports Third Quarter 2007 Financial Results
Date:11/6/2007

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Renovis, Inc. (Nasdaq: RNVS), a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases, today announced financial results for the third quarter ended September 30, 2007.

Revenue for the third quarter and the nine months ended September 30, 2007 was $1.3 million and $8.5 million, respectively, compared to $2.2 million and $8.3 million in the corresponding periods in 2006. All of the revenue earned in the three- and nine-month periods of 2007 related to our collaboration with Pfizer Inc. to research, develop and commercialize small molecules that target the vanilloid receptor, or VR1. The decrease in revenue in the three months ended September 30, 2007 resulted from a change in the amortization period for the upfront license payment that Renovis received from Pfizer in 2005 in connection with the initiation of the collaboration. Following the amendment of that agreement earlier this year to extend the term of the collaboration for an additional year, the amortization period for the upfront license payment was extended, reducing the amount of upfront license fee revenue recognized in each of the first three quarters of 2007. The increase in revenue in the nine months ended September 30, 2007 resulted primarily from the Company's recognition of milestone revenue of $4.5 million from Pfizer partially offset by a decrease in revenue resulting from the revised amortization period as described above. In the corresponding period in 2006 the Company earned $1.5 million in milestone revenue related to the Pfizer collaboration.

Research and development expens
'/>"/>

SOURCE Renovis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 AACC, a global scientific and ... medicine, unveiled an updated brand identity today that reflects ... the changing healthcare environment and continue to do what ... patients get the care they need. ... play an essential role in saving lives and making ...
(Date:8/1/2014)... CHICAGO , Aug. 1, 2014 The  ... increasing the number and success rate of early-stage life ... today that it has awarded 15 grants to help ... AdvaMed 2014: The MedTech Conference   in ... leading MedTech conference in North America ...
(Date:8/1/2014)... , Aug. 1, 2014 Research and ... "Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market ... http://photos.prnewswire.com/prnh/20130307/600769 Single Nucleotide Polymorphism ... variations of SNPs in the genome of various species. ... SNP genotyping and analysis technology can analyze thousands of ...
(Date:8/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , that the global market ... grow to nearly $38.8 billion by 2018, with a ... aptamer delivery category, the fastest moving segment of the ... The field of RNAi therapeutics has shown tremendous growth ...
Breaking Biology Technology:AACC Debuts Refreshed Brand Identity 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3
... fields and tiny iron-bearing particles to drive healthy cells ... in animals, may lead to a new method of ... organs in people. , The study team, led by ... of Pediatric Cardiology at The Childrens Hospital of Philadelphia, ...
... ALTO, Calif., Jan. 7 Telik, Inc. (Nasdaq: ... overview at the,26th Annual JPMorgan Healthcare Conference in San ... Pacific time (10:30 a.m. Eastern,time). A live and archived ... website, http://www.telik.com ., Telik, Inc. of Palo ...
... Potential Blockbuster Product for High Risk Cardiovascular ... ... Calif., Jan. 7 ,Genzyme Corp. (Nasdaq: GENZ ) and Isis ... a major strategic alliance in which,Genzyme will develop and commercialize mipomersen, ...
Cached Biology Technology:Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 2Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 3Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 4Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 5Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 6Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen 7
(Date:7/31/2014)... found to be a key gene responsible for hearing in ... cells of the inner ear that contracts and expands rapidly ... phonograph horn, amplify sound waves to make hearing more sensitivity. ... advanced online edition of Molecular Biology and Evolution , ... independently evolved to play a critical role in the ultrasonic ...
(Date:7/31/2014)... Fla. --- By tracing nearly 3,000 genes to ... University of Florida scientists have created an extensive ... use large-scale, next-generation DNA sequencing. , Among ... closely related to small moths than to large ... butterflies evolved. The study also found that some ...
(Date:7/31/2014)... DARIEN, IL Researchers who studied 100 twin pairs have ... function normally on less than six hours of sleep per ... resistance to the effects of sleep deprivation. , Results show ... BHLHE41 gene had an average nightly sleep duration of ... than the non-carrier twin, who slept for about six hours ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2
... 2011)Regular exercise has proven benefits in preventing and ... tough to meet the American Diabetes Association guidelines of ... A new study, conducted by researchers at McMaster University, ... a small proof-of-principle study in eight type 2 diabetes ...
... How to manage waste has become one of the ... of electrical and electronic equipment that is designed, manufactured and ... and at times highly toxic. Up to 1,200 companies working ... to 10% of their recycling costs thanks to this new ...
... plant growth enhancers are becoming increasingly sought-after. Many ... with limited research capabilities, have not been tested ... effectiveness been documented by scientific data. Researchers from ... effect of Tea Seed Powder (TSP), a saponin-rich ...
Cached Biology News:Exercising harder -- and shorter -- can help Type 2 diabetes 2Exercising harder -- and shorter -- can help Type 2 diabetes 31,200 recycling sector companies will save up to 10 percent thanks to a new system developed by Tecnalia 2Plant growth affected by tea seed powder 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: